The following full text is a publisher's version.

For additional information about this publication click this link. http://hdl.handle.net/2066/14751

Please be advised that this information was generated on 2019-10-17 and may be subject to change.
Hematogenous Candida Vertebral Osteomyelitis Treated with Ketoconazole

Summary: Candida vertebral osteomyelitis was diagnosed in a patient with systemic lupus erythematoses following X-ray evidence of osteomyelitis and the repeated culturing of Candida albicans from material obtained by needle biopsies from the third lumbar vertebra. The patient had been on glucocorticosteroids and parenteral nutrition six months previously. At that time, a yeast was cultured from the blood and the tip of the subclavian catheter which had been removed. After candida vertebral osteomyelitis was diagnosed, she was treated with ketoconazole for seven months. Recovery was impressive, as judged by the clinical and radiographic findings. At the time of writing this paper – 12 months after the withdrawal of ketoconazole – the patient showed no signs of recurrence.


Introduction

Ketoconazole is a new antifungal drug which is absorbed from the gut after oral administration (1). The results obtained in vitro and in experimental animals with coccidiodymycosis and histoplasmosis suggest that this is a potent drug (2-5). Experience in patients with serious fungal infections is limited, and the results are difficult to assess (6). Recently, we successfully used ketoconazole to treat a patient with a deep-seated candida infection.

Case Report

A 30-year-old Chinese woman was admitted to our hospital in March 1980 with a history of backache and vomiting. Systemic lupus erythematoses had been tentatively diagnosed elsewhere in June 1979; the following September, she had been treated with 40 mg prednisone daily for a nephrotic syndrome in another hospital. During that period, the patient received parenteral nutrition. On September 30th, she developed fever and chills; a yeast was cultured from the blood and from the tip of the subclavian catheter which had been removed. No antifungal treatment was given. The pain in the lumbar region had started in January 1980 and had increased steadily, irradiating to the right gluteal area. During the last few days prior to admission, she had been vomiting. She had lost 5 kg bodyweight in the previous two weeks. Physical examination revealed a thin, severely ill woman. She weighed 44 kg and was 160 cm tall. Her temperature was 37°C, pulse rate 64/min and blood pressure 130/70 mmHg. There was slight facial and pretibial edema. The abdomen was swollen and the peristalsis weak. On palpation, the abdomen was diffusely tender. Rectal examination disclosed no abnormalities. A slight swelling was observed on the back to the right of L2. There was percussion pain over L3-L4 and pain at axial pressure. On admission, the erythrocyte sedimentation rate was 68 mm in the first hour (Westergren). The patient had mild anemia: hemoglobin was 7.3 mmol/l and hematocrit 39%. The white cell count was 6.7 x 10^9/l with normal differentiation; the thrombocyte count was 80 x 10^9/l. Renal function was severely impaired (serum creatinine: 85 µmol/l; creatinine clearance: 30 ml/min) and a nephrotic syndrome was present (serum protein concentration: 52 g/l; serum albumin: 19 g/l; urinary protein excretion: 8–22 g/day).

Systemic lupus erythematoses was diagnosed on the basis of proteinuria, thrombocytopenia, strongly positive antinuclear antibodies, a positive LE cell phenomenon (class V A) and a history of pleurisy of unknown cause. The complement profile was in accordance with this diagnosis: C3: 0.20 g/l (normal: 0.55–0.73); C4: 0.05 g/l (0.16–0.27); Clq: 0.53 g/l (0.94–1.22); and CH50: 54 U/ml (185–261).

A lateral tomogram of the lumbar vertebral column showed the typical changes found in spondylitis (Figure 1). The intravenous pyelogram showed displacement of the right ureter and deformation of the right psoas outline by a paravertebral mass.

Received: 17 March 1982

B. A. C. Dijkmans, M. I. Koolen, R. P. Mouton, T. H. M. Falke, P. J. van den Broek, J. W. M. van der Meer

Infection 10 (1982) Nr. 5
Figure 1: Lateral tomogram of the lumbar spine showing sclerosis and cortical destruction of the third vertebral body. Soft tissue calcifications can be seen, with the bridging of a narrowed interspace.

Figure 2: Intravenous pyelography. Tomographic section through the kidneys shows displacement of the right ureter and deformation of the right psoas outline by a paravertebral mass.

Figure 3: CT scan of the third vertebral body at the level of the intervertebral foramen.

Table 1: Serum concentrations of ketoconazole.

<table>
<thead>
<tr>
<th>Time* (h)</th>
<th>During antacid therapy (mg/l)</th>
<th>Without antacid (mg/l)</th>
<th>With hydrochloric acid (mg/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.1</td>
<td>2.3</td>
<td>1.6</td>
</tr>
<tr>
<td>2</td>
<td>1.2</td>
<td>2.1</td>
<td>7.1</td>
</tr>
<tr>
<td>3</td>
<td>N.D.</td>
<td>1.3</td>
<td>6.1</td>
</tr>
<tr>
<td>4</td>
<td>0.2</td>
<td>N.D.</td>
<td>3.2</td>
</tr>
<tr>
<td>8</td>
<td>&lt; 0.2</td>
<td>N.D.</td>
<td>0.7</td>
</tr>
</tbody>
</table>

* after administration
N.D. = not determined

We diagnosed Candida vertebral osteomyelitis with inflammation of the surrounding structures, probably due to hematogenous spread. The intestinal abnormalities were attributed to a reflexory mechanism. Because of impaired renal function, the administration of amphotericin B was considered to be too hazardous. On April 14th, treatment with miconazole was started (600 mg i.v. once daily). After seven days, the patient refused further intravenous therapy, and ketoconazole (400 mg per os four times daily) was started on April 22nd. Serum concentrations of the drug, which were determined microbiologically as described elsewhere (9), were low, even at this high dose (Table 1). Withdrawing the antacid drug improved resorption slightly, but the concomitant administration of 15 ml of
Infection 10 (1982) Nr. 5

B. A. C. Dijkmans et al.: Candida Osteomyelitis

0.03 mol/l hydrochloric acid solution produced much higher levels of ketoconazole in the serum (Table 1). Despite increased activity of the underlying illness, the clinical condition (pain, vomiting) related to the osteomyelitis and the soft tissue inflammation improved dramatically. After seven months of therapy, there were no signs of active infection, and a computerized tomogram showed that the right psoas was normal in size (Figure 3b); ketoconazole was therefore withdrawn in November 1980. Follow-up to the time of writing (November 1981) revealed no evidence of recurrence.

Discussion

Although Candida species are frequently implicated in systemic and local infections, they are seldom mentioned as etiologic agents of osteomyelitis (10). As far as we know, only eight well-documented cases of vertebral osteomyelitis due to Candida species have been reported (11–16). The most important factors predisposing to systemic Candida infection in these patients were hyperalimentation, previous use of antibiotics, bowel surgery and heroin addiction.

Three of the patients reported to have Candida vertebral osteomyelitis were treated with amphotericin B, two were treated with amphotericin B combined with 5-flucytosine, one with 5-flucytosine, one with potassium iodine and one with bed rest without fungostatic therapy. The osteomyelitis was cured in all but one patient, i.e. the patient treated with potassium iodine (15).

At present, the recommended treatment for disseminated Candida infections is amphotericin B alone or in combination with 5-flucytosine (17, 18, 19). The efficacy of imidazole derivatives in the treatment of disseminated Candida infections has not been proven (17, 19, 20). We started to treat our patient with oral ketoconazole because she refused intravenous therapy. High plasma levels were only obtained when the drug was given in an acidified solution; this confirms the findings in volunteers that good absorption of ketoconazole requires a sufficiently low gastric pH (21).

The therapeutic results obtained in our patient suggest that there is a place for ketoconazole in the treatment of disseminated Candida infections; in some cases this may enable us to avoid the use of toxic amphotericin B.

Acknowledgements

The authors would like to thank J. van Cutsem, Janssen Pharmaceutica, Beerse, Belgium, for evaluating the sensitivity of the Candida strain.

Literature